title: Comprehensive Health-Related Quality of Life is Influenced by Nocturia and Sleep Disturbance: Investigation Based on the SF-8.
abstract: We investigated the influence of nocturia and sleep disturbance on health-related quality of life(HRQOL) using the Medical Outcomes Study 8-item Short Form Health Survey (SF-8) in patients with nocturia. We also assessed the effect of therapeutic intervention by means of an anticholinergic agent on the results of the SF-8. One hundred and eighty-four patients who voided at least once per night were surveyed using the SF-8, Overactive Bladder Symptom Score (OABSS), Pittsburgh Sleep Quality Index (PSQI), and Epworth Sleepiness Scale (ESS). These parameters were also evaluated before and after 12 weeks of imidafenacin treatment in 51 patients with OAB accompanied by nocturia. The SF-8 physical component summary score (PCS) showed a significant decrease as nighttime voiding frequency increased. The mental health component summary score was 47.1 and 47.6 (which were lower than the standard value of 50) in the group with a nighttime frequency of once and ≥3/night, respectively. The SF-8 PCS and 6 subscales were negatively associated with nighttime voiding frequency, while the PSQI global score was positively associated with it. Imidafenacin significantly improved the OABSS, PSQI, and ESS, as well as the SF-8 score. This is the first study using the SF-8 to show that nocturia and sleep disturbance have a major influence on comprehensive HRQOL and that the SF-8 can be used to monitor HRQOL in OAB patients receiving treatment for nocturia.
authors.affiliation: Department of Urology, Kurume University School of Medicine.
authors.forename: Shigetaka
authors.initials: S
authors.lastname: Suekane
authors.forename: Kousuke
authors.initials: K
authors.lastname: Ueda
authors.forename: Shunsuke
authors.initials: S
authors.lastname: Suyama
authors.forename: Tokumasa
authors.initials: T
authors.lastname: Hayashi
authors.forename: Noriyuki
authors.initials: N
authors.lastname: Toyozawa
authors.forename: Maki
authors.initials: M
authors.lastname: Yoshitake
authors.forename: Kiyoaki
authors.initials: K
authors.lastname: Nishihara
authors.forename: Nao
authors.initials: N
authors.lastname: Sakashita
authors.forename: Naohisa
authors.initials: N
authors.lastname: Uchimura
authors.forename: Kei
authors.initials: K
authors.lastname: Matsuoka
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D018680:Cholinergic Antagonists / Q000627:therapeutic use; D005260:Female; D006304:Health Status; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D053158:Nocturia / Q000175:diagnosis / Q000188:drug therapy / Q000503:physiopathology / Q000523:psychology*; D011237:Predictive Value of Tests; D011788:Quality of Life; D012890:Sleep; D012893:Sleep Wake Disorders / Q000175:diagnosis / Q000503:physiopathology / Q000523:psychology*; D011795:Surveys and Questionnaires; D013997:Time Factors; D016896:Treatment Outcome; D001743:Urinary Bladder / Q000187:drug effects / Q000503:physiopathology*; D053201:Urinary Bladder, Overactive / Q000175:diagnosis / Q000188:drug therapy / Q000503:physiopathology / Q000523:psychology*; D014563:Urodynamics
chemical_list: D018680:Cholinergic Antagonists; D007093:Imidazoles; C120953:imidafenacin